A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

  • Sarah A. Weiss
  • , Mario Sznol
  • , Montaser Shaheen
  • , Miguel Ángel Berciano-Guerrero
  • , Eva Muñoz Couselo
  • , Delvys Rodríguez-Abreu
  • , Valentina Boni
  • , Lynn M. Schuchter
  • , Maria Gonzalez-Cao
  • , Ana Arance
  • , Wei Wei
  • , Apar Kishor Ganti
  • , Ralph J. Hauke
  • , Alfonso Berrocal
  • , Nicholas O. Iannotti
  • , Frank J. Hsu
  • , Harriet M. Kluger

Producción científica: Article › revisión exhaustiva

33 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy'. En conjunto forman una huella única.

Pharmacology, Toxicology and Pharmaceutical Science